Slide 12010 Thank You, Sponsor! Slide 2 2010 New Leaders/ New Groups Track: Structure a Business Plan that Measures your ERGs Effectiveness Moderator: Brian Sorge / Managing…

Slide 1Compliance Considerations in Pharmaceutical Product Development Compliance Considerations in Pharmaceutical Product Development John C. (Jack) Garvey, Esq. THE WEINBERG…

Slide 1New Zealand Overview Nick Arathimos Investment New Zealand Investment New Zealand Slide 2 What is Investment New Zealand? New Zealand’s investment promotion agency…

1.Value through Innovation ABCD2. Value Through Innovation Boehringer Ingelheim is committed to becoming the most innovative research, development and distribution enterprise…

1. 4/9/[email protected] 2. ICH INTERNATIONAL CONFERENCE ON HARMONIS/ZATION of Technical Requirements for the Registration of Pharmaceuticals for Human4/9/[email protected]…

1. INPUT OUTPUT PROCESS (PROCUREMENT ) Delivered By: ABDUL FAHIM BEM/15505 2. COMPANY INTRODUCTION: • INTRODUCTION • Nawan Laboratories (Pvt.) Ltd. Pakistan is a quality…

Audit report renata limited 2014 Audit report For financial statements Submitted To Mohammad Salahuddin Chowdhury Lecturer Department of Finance University of Dhaka Submitted…

Slide 1 Pharmaceutical Industry and Boehringer Ingelheim Paul Fonteyne Executive Vice President Head of Marketing & Sales, Prescription Medicines Pharmaceutical Industry…

Peter K.S. Siegl, Ph.D. Siegl Pharma Consulting LLC [email protected] SAFETY PHARMACOLOGY: Opportunities and Expectations 8th Annual Safety Pharmacology Society Meeting…

Regulation, Compliance, Culture Or All of the Above? FDA Regulatory and Compliance Symposium August 24, 2006 Speakers Ann Beasley Bacon Compliance Counsel, Boehringer Ingelheim…